The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients

We evaluated glaucoma patients for the efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1%. A total of 22 glaucoma patients were enrolled and completed this prospective, nonrandomized stu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hiromitsu Onoe, Kazuyuki Hirooka, Mikio Nagayama, Atsushi Hirota, Hideki Mochizuki, Takeshi Sagara, Katsuyoshi Suzuki, Hideaki Okumichi, Yoshiaki Kiuchi
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	glaucoma brinzolamide brimonidine satisfaction Medicine R
Acceso en línea:	https://doaj.org/article/6fa3f659028946dfb297d7ceddd3d563
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6fa3f659028946dfb297d7ceddd3d563
record_format	dspace
spelling	oai:doaj.org-article:6fa3f659028946dfb297d7ceddd3d5632021-11-25T18:00:40ZThe Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients10.3390/jcm102252282077-0383https://doaj.org/article/6fa3f659028946dfb297d7ceddd3d5632021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5228https://doaj.org/toc/2077-0383We evaluated glaucoma patients for the efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1%. A total of 22 glaucoma patients were enrolled and completed this prospective, nonrandomized study that evaluated patients who underwent treatment with at least brinzolamide 1% and brimonidine 0.1%. Patients on brinzolamide 1% and brimonidine 0.1% were switched to a brinzolamide/brimonidine fixed-combination ophthalmic suspension (BBFC). Evaluations of intraocular pressure (IOP), superficial punctate keratopathy (SPK) and conjunctival hyperemia were conducted at baseline and at 4 and 12 weeks. The Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) was utilized to assess the change in treatment satisfaction. At baseline and at 4 and 12 weeks, the IOP was 15.0 ± 4.1, 14.8 ± 4.1 and 14.8 ± 4.1 mmHg, respectively. There were no significant differences observed at any of the time points. However, the SPK score significantly decreased at 12 weeks, even though no significant differences were observed for the conjunctival hyperemia incidence at any of the time points. After switching from brinzolamide 1% and brimonidine 0.1% to BBFC, there was a significant increase in the TSQM-9 score for convenience and global satisfaction. Both an improvement in the degree of SPK and an increase in treatment satisfaction occurred after switching from brinzolamide 1% and brimonidine 0.1% to BBFC, even though there were sustained IOP values throughout the 12-week evaluation period.Hiromitsu OnoeKazuyuki HirookaMikio NagayamaAtsushi HirotaHideki MochizukiTakeshi SagaraKatsuyoshi SuzukiHideaki OkumichiYoshiaki KiuchiMDPI AGarticleglaucomabrinzolamidebrimonidinesatisfactionMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5228, p 5228 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glaucoma brinzolamide brimonidine satisfaction Medicine R
spellingShingle	glaucoma brinzolamide brimonidine satisfaction Medicine R Hiromitsu Onoe Kazuyuki Hirooka Mikio Nagayama Atsushi Hirota Hideki Mochizuki Takeshi Sagara Katsuyoshi Suzuki Hideaki Okumichi Yoshiaki Kiuchi The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
description	We evaluated glaucoma patients for the efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1%. A total of 22 glaucoma patients were enrolled and completed this prospective, nonrandomized study that evaluated patients who underwent treatment with at least brinzolamide 1% and brimonidine 0.1%. Patients on brinzolamide 1% and brimonidine 0.1% were switched to a brinzolamide/brimonidine fixed-combination ophthalmic suspension (BBFC). Evaluations of intraocular pressure (IOP), superficial punctate keratopathy (SPK) and conjunctival hyperemia were conducted at baseline and at 4 and 12 weeks. The Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) was utilized to assess the change in treatment satisfaction. At baseline and at 4 and 12 weeks, the IOP was 15.0 ± 4.1, 14.8 ± 4.1 and 14.8 ± 4.1 mmHg, respectively. There were no significant differences observed at any of the time points. However, the SPK score significantly decreased at 12 weeks, even though no significant differences were observed for the conjunctival hyperemia incidence at any of the time points. After switching from brinzolamide 1% and brimonidine 0.1% to BBFC, there was a significant increase in the TSQM-9 score for convenience and global satisfaction. Both an improvement in the degree of SPK and an increase in treatment satisfaction occurred after switching from brinzolamide 1% and brimonidine 0.1% to BBFC, even though there were sustained IOP values throughout the 12-week evaluation period.
format	article
author	Hiromitsu Onoe Kazuyuki Hirooka Mikio Nagayama Atsushi Hirota Hideki Mochizuki Takeshi Sagara Katsuyoshi Suzuki Hideaki Okumichi Yoshiaki Kiuchi
author_facet	Hiromitsu Onoe Kazuyuki Hirooka Mikio Nagayama Atsushi Hirota Hideki Mochizuki Takeshi Sagara Katsuyoshi Suzuki Hideaki Okumichi Yoshiaki Kiuchi
author_sort	Hiromitsu Onoe
title	The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
title_short	The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
title_full	The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
title_fullStr	The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
title_full_unstemmed	The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
title_sort	efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1% in glaucoma patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6fa3f659028946dfb297d7ceddd3d563
work_keys_str_mv	AT hiromitsuonoe theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT kazuyukihirooka theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT mikionagayama theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT atsushihirota theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT hidekimochizuki theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT takeshisagara theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT katsuyoshisuzuki theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT hideakiokumichi theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT yoshiakikiuchi theefficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT hiromitsuonoe efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT kazuyukihirooka efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT mikionagayama efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT atsushihirota efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT hidekimochizuki efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT takeshisagara efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT katsuyoshisuzuki efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT hideakiokumichi efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients AT yoshiakikiuchi efficacysafetyandsatisfactionassociatedwithswitchingfrombrinzolamide1andbrimonidine01toafixedcombinationofbrinzolamide1andbrimonidine01inglaucomapatients
_version_	1718411749738151936

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients

Ejemplares similares